NASDAQ:SNOA Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis $0.72 -0.09 (-10.83%) Closing price 04:00 PM EasternExtended Trading$0.72 -0.01 (-0.69%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Sonoma Pharmaceuticals Stock (NASDAQ:SNOA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sonoma Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.72▼$0.8450-Day Range$0.81▼$1.3052-Week Range$0.72▼$3.95Volume103,745 shsAverage Volume82,674 shsMarket Capitalization$3.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Sonoma Pharmaceuticals develops and markets products based on its stabilized hypochlorous acid technology for human and animal health. Its product portfolio includes solutions and gels for wound care, skin conditions, eye care and other hygiene applications. The company’s offerings include Microcyn-branded products, which are used in areas such as wound management and dermatology, as well as products for veterinary care. Sonoma sells its products through commercial partners and distributors in the United States and international markets. The company was formerly known as Oculus Innovative Sciences and adopted the Sonoma Pharmaceuticals name in 2016. Its business has since focused on developing and commercializing hypochlorous acid-based products for healthcare and related markets.AI Generated. May Contain Errors. Read More Sonoma Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreSNOA MarketRank™: 0.58173076923 of 5 starsSonoma Pharmaceuticals scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingSonoma Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSonoma Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Sonoma Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sonoma Pharmaceuticals is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sonoma Pharmaceuticals is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSonoma Pharmaceuticals has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.41% of the float of Sonoma Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSonoma Pharmaceuticals has a short interest ratio ("days to cover") of 1.67, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sonoma Pharmaceuticals has recently decreased by 38.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSonoma Pharmaceuticals does not currently pay a dividend.Dividend GrowthSonoma Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows3 people have added Sonoma Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sonoma Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders1.02% of the stock of Sonoma Pharmaceuticals is held by insiders.Percentage Held by Institutions1.95% of the stock of Sonoma Pharmaceuticals is held by institutions.Read more about Sonoma Pharmaceuticals' insider trading history. Receive SNOA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNOA Stock News HeadlinesSonoma Pharmaceuticals Cancels Adjourned Special Stockholder MeetingAugust 19, 2026 | tipranks.comSonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly RevenueAugust 6, 2026 | benzinga.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 20 at 1:00 AM | Paradigm Press (Ad)Sonoma Pharmaceuticals Expands At-the-Market Equity Offering CapacityJune 18, 2026 | tipranks.comSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial ResultsJune 16, 2026 | finanznachrichten.deWhat's going on with Sonoma Pharma stock Monday?April 27, 2026 | msn.comSonoma Pharmaceuticals Announces Pricing of $4 Million Public OfferingApril 25, 2026 | finance.yahoo.comSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and WalmartMarch 24, 2026 | finanznachrichten.deSee More Headlines SNOA Stock Analysis - Frequently Asked Questions How have SNOA shares performed this year? Sonoma Pharmaceuticals' stock was trading at $3.64 at the beginning of the year. Since then, SNOA stock has decreased by 80.2% and is now trading at $0.7220. How were Sonoma Pharmaceuticals' earnings last quarter? Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) released its earnings results on Tuesday, November, 10th. The company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.19. The business had revenue of $7.17 million for the quarter, compared to analyst estimates of $5.29 million. Sonoma Pharmaceuticals had a negative trailing twelve-month return on equity of 4.82% and a negative net margin of 7.65%. How do I buy shares of Sonoma Pharmaceuticals? Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sonoma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sonoma Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), American Airlines Group (AAL), BigBear.ai (BBAI) and GE Aerospace (GE). Company Calendar Last Earnings11/10/2026Today11/20/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SNOA's financial health is in the Red zone, according to TradeSmith. SNOA has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SNOA CIK1367083 Webwww.sonomapharma.com Phone(800) 759-9305Fax707-283-0551Employees260Year Founded1999Profitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.17 million Net Margins-7.65% Pretax Margin-5.93% Return on Equity-4.82% Return on Assets-1.52% Debt Debt-to-Equity RatioN/A Current Ratio3.48 Quick Ratio2.68 Sales & Book Value Annual Sales$19.53 million Price / Sales0.19 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book0.55Miscellaneous Outstanding Shares5,060,000Free Float5,010,000Market Cap$3.65 million OptionableNot Optionable Beta1.31 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:SNOA) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.